Rajaie Cardiovascular Medical and Research Center
14
1
2
3
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 50/100
14.3%
2 terminated/withdrawn out of 14 trials
60.0%
-26.5% vs industry average
57%
8 trials in Phase 3/4
0%
0 of 3 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (14)
AI-Based Prediction Model for Iliofemoral DVT Thrombolysis
Role: lead
Coated or Chewable Aspirin and a Hybrid Strategy to Mitigate Adverse Effects of Air Pollution in Stable Atherosclerotic Disease
Role: lead
Empagliflozin to Prevent Post-Operative Atrial Fibrillation
Role: lead
Rivaroxaban vErsus Warfarin for Antithrombotic TheRapy in Patients With LeFt Ventricular Thrombus After Acute STEMI
Role: lead
Compression Stockings for Treating Vasovagal Syncope Trial
Role: collaborator
Cardiopulmonary Bypass Prime Solution in Patients Undergoing Heart Valve Surgery
Role: lead
Catheter-Directed Thrombolysis Versus Anticoagulation Monotherapy in Intermediate-High Risk PE
Role: lead
RIvoraxaban in Mitral Stenosis
Role: lead
Intermediate-dose vs Standard Prophylactic Anticoagulation and Statin vs Placebo in ICU Patients With COVID-19
Role: lead
Midodrine and Fludrocortisone for Vasovagal Syncope
Role: collaborator
Rajaie Cardiomyopathy and Myocarditis Registry
Role: lead
Efficacy and Safety of Ivabradine to Reduce Heart Rate Prior to Coronary CT-angiography in Advanced Heart Failure: Comparison With β-Blocker
Role: lead
Vitamin E and N-acetylcysteine for Preventing Contrast-Induced Acute Kidney Injury After Coronary Artery Catheterization
Role: lead
Safety and Efficacy of High Protein Diet Versus GFR Based Protein Diet in Heart Failure Patients With Renal Insufficiency
Role: lead
All 14 trials loaded